MoU Signed With ECHS Regional Centre
The All India Institute of Medical Sciences (AIIMS) Guwahati will offer specialised healthcare services to former defence personnel and their families under the government’s Ex-Servicemen Contributory Health Scheme (ECHS), officials said. A Memorandum of Understanding (MoU) was signed with the ECHS Regional Centre, Guwahati, on February 6, 2026, at the institute.
Expanded Medical Access for Veterans
The collaboration is expected to ensure comprehensive healthcare services for ex-servicemen and their dependents across the northeastern region, according to an official statement quoted by news agency PTI.
Focus on Quality Healthcare Delivery
Officials said the agreement aims to improve access to quality medical care for veterans and their families, thereby strengthening healthcare support mechanisms for former defence personnel in the region.
Specialised Services at AIIMS Guwahati
Under the partnership, eligible beneficiaries registered under the Ex-Servicemen Contributory Health Scheme will be able to avail specialised medical treatment and facilities at AIIMS Guwahati, in line with applicable norms and guidelines, the statement added.
Strengthening Healthcare Infrastructure
The initiative is expected to ease the healthcare burden on ex-servicemen by providing them access to advanced medical infrastructure and specialist services at one of the region’s premier healthcare institutions.
AIIMS Guwahati’s Growing Regional Role
AIIMS Guwahati has been playing an increasingly important role in strengthening tertiary healthcare services and medical education in the northeastern states.
Clinical Trial Unit Launched Earlier
Earlier, AIIMS Guwahati inaugurated a Clinical Trial Unit (CTU) aimed at promoting high-quality, ethical, and patient-centred clinical research in the region. The facility is designed to support both regional and national health research priorities.
Boost to Research and Innovation
Speaking at the inauguration, AIIMS Executive Director Ashok Puranik said the CTU would enable investigators to conduct rigorous studies, catalyse investigator-initiated and sponsor-led trials, improve patient access to cutting-edge therapies, and help build a sustainable research talent pipeline.
